Cantor Fitzgerald Maintains Overweight on Innoviva, Lowers Price Target to $34

Benzinga Newsdesk www.benzinga.com Negative 91.7%

Neg 91.7% Neu 0% Pos 0%

Cantor Fitzgerald analyst Steve Seedhouse maintains Innoviva (NASDAQ:INVA) with a Overweight and lowers the price target from $36 to $34.